Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
3.840
+0.010 (0.26%)
Feb 24, 2025, 11:45 AM EST - Market open
Genfit Revenue
Genfit had revenue of 61.10M EUR in the half year ending June 30, 2024, with 403.23% growth. This brings the company's revenue in the last twelve months to 80.47M, up 175.45% year-over-year. In the year 2023, Genfit had annual revenue of 34.48M with 31.38% growth.
Revenue (ttm)
80.47M EUR
Revenue Growth
+175.45%
P/S Ratio
2.24
Revenue / Employee
506,126 EUR
Employees
159
Market Cap
192.83M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
Dec 31, 2019 | 38.97M | 31.61M | 429.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GNFT News
- 3 days ago - GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting - GlobeNewsWire
- 9 days ago - GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders - GlobeNewsWire
- 17 days ago - GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 - GlobeNewsWire
- 25 days ago - GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan - GlobeNewsWire
- 25 days ago - GENFIT Announces 2025 Financial Calendar - GlobeNewsWire
- 5 weeks ago - GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewsWire
- 3 months ago - GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 - GlobeNewsWire
- 3 months ago - GENFIT Reports Third Quarter 2024 Financial Information - GlobeNewsWire